Allantoin is a heterocyclic organic compound. Allantoin ascorbate, allantoin biotin, allantoin galacturonic acid, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid are complexes of allantoin. All of the ingredients in this review act as skin-conditioning agents. Allantoin was reported to be used in 1376 cosmetic products at concentrations up to 2%. There are data gaps regarding use and concentration of the remaining allantoin complexes. Ascorbic acid, biotin, glycyrrhetinic acid, and panthenol have been determined by the CIR Expert Panel to be safe. Galacturonic acid and polygalacturonic acid have not been reviewed by the CIR Expert Panel, and substantial data on these chemicals were not available. The safety test data in this safety assessment and in previous safety assessments were considered sufficient to support the safety of allantoin and the allantoin complexes in product categories and at concentrations reviewed in this safety assessment. This is a safety assessment of the cosmetic ingredient allantoin and the related complexes allantoin ascorbate, allantoin biotin, allantoin galacturonic acid, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid.
hexahydro-2-oxo-, compd. with (2,5-dioxo-4-imidazolidinyl) urea (1:1). 7 Allantoin galacturonic acid (CAS No. 5119- is the complex of allantoin and galacturonic acid that conforms to the formula in Figure 1D . Its chemical classes are heterocyclic compounds and organic salts. It is also known as allantoin a-D-galacturonic acid; allantoin, monogalactopyranuronat; and galactopyranuronic acid, compd. with allantoin (1:1). 7 Allantoin glycyrrhetinic acid (CAS No. 4572-09-2) is a complex of allantoin and glycyrrhetinic acid and has the empirical formula: C30H46O4 Á C4H6N4O3. Its chemical classes are heterocyclic compounds and organic salts. It is also known as olean-12-en-29-oic acid, 3b-hydroxy-11-oxo-, compd. with allantoin (1:1). 7 Allantoin panthenol (no CAS No.) is a complex between allantoin and panthenol. Its chemical classes are alcohols, amides, and heterocyclic compounds. A technical name is allantoin DL-pantothenyl alcohol. 7 Allantoin polygalacturonic acid (CAS No. 29659- ) is a complex of allantoin and polygalacturonic acid. Its chemical classes are heterocyclic compounds and organic salts. Allantoin polygalacturonic acid has the empirical formula (C6H10O7)x Á xC4H6N4O3. 7 
Physical and Chemical Properties
Allantoin is a white powder 8, 9 that is odorless and tasteless 10, 11 and does not stain. 12 Allantoin is an amphoteric substance. 13 Chemical properties of allantoin are listed in Table 2 . Akema Fine Chemicals 11 stated that allantoin exists in solution as a tautomeric mixture of ketonic and enolic forms in equilibrium. With 1 chiral center, the 2 enantiomeric forms R and S are a 50:50 mixture that is optically inactive. Optically active forms can be obtained by extraction procedures.
Allantoin is soluble in hot water; slightly soluble in cold water, glycerin, and propylene glycol; very slightly soluble in alcohol; and practically insoluble in apolar solvents (ie, mineral oil, dimethylisosorbide, ether, and chloroform). 11 Allantoin ascorbate is a white-yellowish powder that is water soluble. 17 Allantoin a-D-galacturonic acid is soluble at 3% to 5%. It contains *41.6% + 4.0% allantoin and *58.4% + 4.0% a-D-galacturonic acid. 18 Allantoin glycyrrhetinic acid, as described in a product data sheet by Active Ingredients Ltd, 19 is the combination of allantoin and glycyrrhetinic acid in molar ratios of 1:1, 1:2, or 1:3. The product specification states that allantoin, measured as nitrogen, is 30% + 2% and glycyrrhetinic acid is 70% + 65 2 Safe for use in cosmetic formulations in the practices of use and concentration as described in this safety assessment. Panthenol d,e 284 0.1-5 Safe as presently used in cosmetics. 2% of the complex. It is a yellowish-white powder with a mild, characteristic odor. Allantoin glycyrrhetinic acid is soluble in propylene glycol, dimethylisosorbide, and alcohol; it is practically soluble in water and mineral oil. In a product data sheet, Akema Fine Chemicals 17 states that allantoin glycyrrhetinic acid is a white-yellowish powder that is alcohol soluble but not water soluble. It has a working temperature of up to 80 C. Allantoin panthenol, as described in a product data sheet by Akema Fine Chemicals, 17 is a white powder that is water soluble.
Allantoin polygalacturonic acid, as described in a product data sheet by Akema Fine Chemicals, 17 is a white-yellowish powder. It forms a clear thin gel in sodium citrate solution.
Stability
Allantoin degrades when dissolved in distilled water. At 0.13% allantoin (0.6556 g per 500 mL), 6.3% was lost after 620 days; at 0.45% (1.1396 g per 250 mL), 1.5% was lost after 415 days; at 0.24% (2.421 g per 1000 mL), 6.4% was lost after 24 days. At 0.13% allantoin in tap water, 6.4% was lost after 24 days. When 2 samples of allantoin (25 mL) were mixed with 23.94 mL of potassium hydroxide (KOH) and let stand for a month, there was a 90.2% loss and a 91.1% loss. When 2 samples of allantoin (25 mL) were incubated in KOH (20 mL) for 24 hours (at ''body temperature''), there was a 43.4% loss of allantoin. 20 Kaliszan and Halkiewicz 21 used infrared (IR) analysis to look for deterioration in stored allantoin. After 3 months, the samples differed at *720 cm -1 in the position of V amide band of the hydrogen-bonded secondary amides and in the formation of the III amide band at 1275 cm -1 . The samples also differed at the region of N-H rocking vibrations (666-800 cm -1 ).
Allantoin is unstable in alkaline conditions and hydrolyzes to urea and glyoxylic acid, possibly via allantoic acid. 22 However, it is stable in ordinary conditions. 9 It should be stored at room temperature away from sunlight. 12 Sznitowska and Janicki 23 measured the release of allantoin from various ointments using a modified Mutimer apparatus. At 150 minutes, more than 80% of the allantoin from the oil/ water ointment (15% wt/wt oily phase and 84% wt/wt aqueous ethanol phase) was released with a solubility of 1.12 g/cm 3 . At 300 minutes, *50% of the allantoin from the water/oil ointment (73% wt/wt oily phase and 26% wt/wt aqueous ethanol phase) was released with a solubility of 0.78 g/cm 3 . At 300 minutes, *50% of the oil/water ointment (no wt/wt oily phase and 94% wt/wt aqueous ethanol phase) was released with a solubility of 0.97 g/cm 3 .
Allantoin glycyrrhetinic acid has a shelf life of 5 years in the original packaging. 19 
UV Absorption
Lukasiak et al 24 reported that the absorption of allantoin in aqueous solution is most stable at a pH range of 10.5 to 11.5 at lmax ¼ 225 nm.
Methods of Manufacture
Allantoin can be extracted from blow-fly larvae 25 and maize silk. 26 According to Hartman et al, 27 allantoin is prepared from the heated combination of uric acid and sodium hydroxide with the addition of potassium permanganate to the cooled flask. The solution is filtered to remove manganese dioxide, and acetic acid is added. After standing for several hours, allantoin crystallizes and can be filtered. To further purify the filtrate, the allantoin is dissolved in boiling water, treated with Norite, and then rapidly filtered again.
Akema Fine Chemicals 28 reported that it manufactures allantoin by chemical means and does not use any animal sources.
Akema Fine Chemicals 11 also reported that allantoin is synthetically obtained by oxidation of uric acid with permanganate, heating of dichloroacetic acid and urea, and a condensation process between glyoxylic acid and urea.
The International Cosmetic Ingredient Dictionary and Handbook stated that allantoin has a synthetic source for use in cosmetics. 7 
Analytical Methods
Analytical methods for measuring allantoin under different circumstances and conditions are listed in Table 3 .
Impurities
Allantoin. Kahn and Nolan 41 reported that [4,514C] allantoin was 96.0% pure by thin-layer chromatography (TLC) and 96.3% pure by high-performance liquid chromatography (HPLC).
Wang et al 42 gave the purity of allantoin powder from Jiangsu Huanghai Pharmaceutical Factory as 99.6%. Impurities have been reported to include sulfated ash (0.1%-0.2%), sulfate (200 ppm), chloride (50 ppm), heavy metals (10 ppm), lead (<20 ppm), iron (10 ppm), arsenic (3 ppm), urea (0.5%), glyoxylic acid (0.5%), and glycoluril (<0.2%). 9, 11, 19 
Natural Occurrence in Plants and Food
Allantoin is found naturally in the leaf buds of Platanus orientalis (oriental plane tree), Acer pseudoplatanus (sycamore), and Acer campestre (hedge maple) and in the bark of Aesculus hippocastanum (horse chestnut) and A pseudoplatanus. Allantoin is also found in the embryos of wheat separated in the milling process and in beet juice. 43 Allantoin has been found in trace amounts in other plants and in foods. 11, 26, 44 
Use Cosmetic
According to the International Cosmetic Ingredient Dictionary and Handbook, 7 allantoin functions as a skin-conditioning agent -miscellaneous and a skin protectant. Allantoin ascorbate, allantoin biotin, allantoin galacturonic acid, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid also act as skin-conditioning agents -miscellaneous. 7 According to information supplied to the FDA by industry as part of the Voluntary Cosmetic Ingredient Reporting Program (VCRP), allantoin is used in a total of 1376 cosmetic products. 45 A survey of current use concentrations conducted by the Cosmetic, Toiletry, and Fragrance Association (CTFA) reported that allantoin is used at concentrations ranging from 0.0001% to 2%. 46 Allantoin ascorbate was reported by industry to be used at concentrations of 0.001% and 0.05% for allantoin biotin and allantoin galacturonic acid. Table 4 summarizes the available cosmetic use data on frequency of use and concentrations of use of allantoin and allantoin complexes.
Allantoin glycyrrhetinic acid was reported to be used in 6 cosmetic products, allantoin panthenol in 2 cosmetic products, and allantoin polygalacturonic acid in 2 cosmetic products 47 ; concentrations of use were not reported to CTFA.
The Ministry of Health, Labor and Welfare 48 of Japan lists allantoin as an acceptable medicinal ingredient to be used in cosmetics.
Allantoin is used in 11 sprays and fixatives. The potential adverse effects of inhaled aerosols depend on the specific chemical species, the concentration, the duration of the exposure, and the site of deposition within the respiratory system. 49 In general, the smaller the particle, the farther into the respiratory tree the particle will deposit and the greater the impact on the respiratory system. 50 Anhydrous hair spray particle diameters of 60 to 80 mm have been reported, and pump hair sprays have particle diameters of 80 mm or larger. 51 The mean particle diameter is around 38 mm in a typical aerosol spray. 52 In practice, aerosols should have at least 99% of particle diameters in the 10-to 110-mm range. This means that most aerosol particles are deposited in the nasopharyngeal region and are not respirable.
Noncosmetic
Allantoin is FDA approved for use as a skin protectant at 0.5% to 2.0%. 53 It is considered safe for use as an oral wound healing agent, but there are inadequate data to establish the effectiveness. 45 Allantoin for a variety of other skin uses has been described. 25, [54] [55] [56] [57] The safety and effectiveness of allantoin for use in dandruff/ seborrheic dermatitis psoriasis drug products have not been established. 58 Use of allantoin ascorbate, allantoin polygalacturonic acid, allantoin glycyrrhetinic acid, and allantoin polygalacturonic acid in various skin treatments has been described by manufacturers. 18, 19, 59 General Biology Most mammals process purines to allantoin, as shown in Figure 2 . However, higher apes and humans do not possess urate oxidase, the final step in the process; thus, purines in humans become uric acid, which is excreted in urine. 60 The oxidation of uric acid by cytochrome c produced allantoin. This may be a possible source of allantoin in human tissues and may be of significance in patients with Reye's syndrome, in whom elevated uric acid has been demonstrated. 61 
Animals and Humans
Allantoin is found in blood or serum in humans in the range of 7.2 to 48.2 mmol/L. 31, 33, 36, [62] [63] [64] [65] Absorption, Distribution, Metabolism, and Excretion Sznitowska and Janicki 66 applied allantoin (1%) in 3 different vehicles to the inner forearm of volunteers (n ¼ 6) to test skin penetration. The vehicles were a hydrophilic gel (5% wt/wt aqueous solution of methyl cellulose with added glycerol and propylene glycol), an oil/water cream (sodium lauryl sulfate and cetostearyl alcohol), and a water/oil ointment (cetyl alcohol and cholesterol). Two applications of each vehicle were made, 1 removed after 3 hours and the other after 6 hours. The remaining allantoin in the removed portion was measured and subtracted from the original amount to determine the absorption of allantoin. Allantoin penetration with the hydrophilic gel at 3 and 6 hours was 5.00% + 1.25% and 6.9% + 1.4%, respectively; with the oil/water cream 13.0% + 1.8% and 15.4% + 2.7%, respectively; and with the water/oil ointment 12.5% + 2.1% and 20.0% + 2.3%, respectively. Allantoin (600 mg) was administered by stomach tube to dogs. 67 Elimination was complete in *4 hours. Urine allantoin peaked at *260 mg per 100 mL in less than 30 minutes and declined rapidly. Blood allantoin peaked at *90 mg per 100 mL in less than 1 hour and declined steadily. Recovery was 674 mg (112%).
Friedman and Byers 68 performed clearance studies on male albino rats (n ¼ 20; 1 was used twice) and male dogs (n ¼ 4; 9 runs were done) following intravenous (IV) administration of allantoin. The renal clearance of endogenous allantoin in rats was 33.7 mL/h per 100 g (range, 25.8-41.7 mL/h per 100 g). The mean plasma allantoin concentration was 1.76 mg% (range, 1.20-2.23 mg%) during clearance. The renal clearance of endogenous allantoin in dogs was 85.5 mL/ min/m 2 (range, 1.46-7.55 mL/g per 100 g). The mean plasma allantoin concentration was 0.66 mg% (range, 0.40-1.03 mg%).
Wallenburg and van Kreel 69 tested the transference of allantoin from the fetus to the dam in a pregnant rhesus monkey (Macaca mulatta). The dam was anesthetized. After fasting, a lower midline laparotomy was performed and the uterus exposed and delivered from the abdominal cavity. A fetal leg was delivered through a small incision and dissected for the application of catheters to the fetal femoral artery and vein. The fetal groin was sutured and returned to the amniotic cavity after draining the urinary bladder. The uterus was returned to the abdominal cavity and the incision partially closed. The maternal aorta, through a femoral artery, and the vena cava, through a saphenous vein, were catheterized. [ 14 C]Allantoin was infused into the fetal femoral artery (10 mL/g of body weight for 30 minutes and then 3 mL/h). Samples were collected from the fetal femoral artery (0.4 mL) and from the maternal aorta (1.0 mL) at 15-minute intervals and stored in heparinized vials. After centrifugation, fetal red cells were suspended in an equal volume of dilute heparin-normal saline and reinjected into the fetal circulation. The fetus was delivered by Cesarean section and killed, and the urinary bladder was emptied.
The total fetal clearance of allantoin was 3.8 mL/min/kg; renal clearance of allantoin was 0.09 mL/min/kg and of creatinine 0.29 mL/min/kg. The total clearance of allantoin was similar to that of uric acid clearance. Unlabeled uric acid in the fetal plasma was 60 mmol/L at the beginning of the experiment and rose 2-to 3-fold; steady concentration levels were never observed. Maternal renal uric acid and creatinine clearances were 3.2 + 0.6 and 3.0 + 0.5 mL/min/kg, respectively, and maternal plasma unlabeled uric acid remained stable at a low level (1.54 + 0.30 mmol/L). Less than 5% of the available uric acid metabolized to allantoin. The authors stated that it is unlikely that fetal uric acid contributes to the maternal uric acid load in pre-eclamptic pregnancies. 69 
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Animal Toxicology
No short-term or subchronic toxicity data were available. Chronic toxicity data are presented in the Carcinogenicity section.
Oral Acute Toxicity
In a toxicology assessment, 70 an acute oral toxicity test on Wistar rats (n ¼ 10, 5 males and 5 females) was performed. The rats were orally administered a single dose of allantoin (5000 mg/kg) and observed for 14 days. No clinical signs were observed during the observation period. No mortality occurred.
No abnormalities were noted at necropsy. Akema Fine Chemicals 11 reported the oral median lethal dose (LD 50 ) of allantoin in rats to be more than 5000 mg/kg and considered allantoin to be slightly toxic.
Acute Dermal Toxicity
Akema Fine Chemicals 11 reported the LD 50 of allantoin on the intact and abraded skin of rabbits (n ¼ 10) to be 5000 mg/kg or higher.
Ocular Irritation
Centre International de Toxicoligie 71 performed a primary ocular irritancy test of allantoin (100 mg) on 1 eye of New Zealand rabbits (n ¼ 6). The other eye served as the control. The eyes were examined 1, 24, 72, and 96 hours after instillation. No ocular reactions were observed. The authors concluded that allantoin was not irritating to eyes. Akema Fine Chemicals 11 reported that no eye irritation was observed in a Draize test on rabbits without washout (details not provided).
Phototoxicity
No phototoxicity or photosensitization data were available.
Reproductive and Developmental Toxicity
No reproductive or developmental toxicity data were available.
Genotoxicity
Allantoin was not mutagenic to Salmonella typhimurium strains TA1535, TA1538, TA98, and TA100, with or without S9 up to 1000 mg. 72 Gus'kov et al 73 measured the frequency of rifampicinresistant mutants in the Escherichia coli SOS-lux test to measure the mutagenicity of allantoin. Allantoin (1 mL) was added to the test plates 1.5 hours before hydrogen peroxide (10 -7 and 10 -6 M) was added to plates containing E coli (PT-1 strain transformed with plasmid pPls-1 carrying the Lux operon controlled by an SOS-responder). Water was the control. Allantoin decreased the mutant frequency at both hydrogen peroxide concentrations (P < .05). In further testing, allantoin did not affect the induction of the SOS response when added simultaneously with the hydrogen peroxide. When allantoin was added 1.5 hours before and after hydrogen peroxide, the mutations decreased (P < .001 and .01, respectively).
Akema Fine Chemicals 11 reported that allantoin was not mutagenic in an Ames test.
Dermal Irritation
Akema Fine Chemicals 11 reported that allantoin (0.5% in water) was not a primary skin irritant when applied to the intact and abraded skin of rabbits (details not provided).
Shiseido Research Center 74 applied allantoin (10% in water) to the clipped and shaved flanks of guinea pigs (n ¼ 3) daily for 3 days. The skin was evaluated 24 hours after each application. The cumulative irritation score index was 0.2. The authors concluded that allantoin is classified as a ''none to weak irritant'' and is safe for use as a cosmetic ingredient.
The authors treated the germinated roots of Allium cepa L. (onion) with hydrogen peroxide after treating them with allantoin (10 -6 to 10 -5 M). After 18 hours, the seedlings were fixed and examined for aberrant cells, and chromosomal aberrations were quantified and compared with untreated seedlings. The treated seedlings decreased the level of Fe 2þ -induced chromosomal aberrants (P < .001). The level of chromosomal aberrations decreased after 42 hours (P < .01). The authors stated that allantoin is neither cytotoxic nor cytostatic while exerting antimutagenic effects at concentrations corresponding to physiological values (ie, blood plasma 6.5 Â 10 -6 ). 75 
Carcinogenicity
Lijinsky 76 fed F344 rats (males and females) rat chow with and without 0.2% allantoin with or without 0.2% sodium nitrite ad libitum for 106 weeks (n ¼ 20). The rats were necropsied and all gross lesions and major organs and tissues were examined histologically. Controls (n ¼ 24) were fed untreated chow and tap water.
The approximate total doses of allantoin were calculated to be 42 g per male rat and 28 g per female rat. Most of the rats were alive at the end of the 2-year treatment; there was no difference in the life spans of the rats in any group. The incidence of nonneoplastic lesions of the organs did not differ between treated and control rats. There was no difference in the incidence of tumors between groups. There was an increase in papillomas of the forestomach in male rats fed allantoin plus nitrite compared with controls (P < .047). The incidence of pituitary tumors was lower in females, but not males, fed allantoin without nitrite than in the untreated or nitrite-treated controls (P not provided). 76 Clinical Assessment of Safety Absorption, Distribution, Metabolism, and Excretion Young et al 67 administered allantoin to male subjects orally, intravenously, and subcutaneously. Almost all of the allantoin administered by IV and subcutaneous injection was recovered by urinary excretion within 2 days; less was recovered following oral administration. The authors suggest that allantoin goes through decomposition in the intestine prior to absorption.
Friedman et al 77 measured the clearance of orally administered allantoin in 5 men and 1 woman. The volunteers were administered 10 g of allantoin. The average plasma clearance of allantoin at 3.0, 3.5, and 4.0 hours after ingestion was 5.9, 5.9, and 6.2 mg per 100 mL, respectively, and the average renal clearance of allantoin was 123, 123, and 123 mL/min, respectively. No adverse effects were observed as a result of allantoin ingestion. 77 Freidman et al 78 repeated the above experiment on healthy volunteers (n ¼ 9; 1 female, 8 males) and patients with hypertension (n ¼ 8; 3 female, 5 male), coarctation (n ¼ 1 male), or nephritis (n ¼ 2; 1 female, 1 male). The procedure was repeated with inulin (10 g in saline intravenously). The authors concluded that allantoin clearance was a measure of glomerular filtration rate; allantoin is absorbed by the gastrointestinal tract at a stable rate. There were no signs of toxicity following ingestion of allantoin. 78 Dermal Irritation and Sensitization Mecca 79 reported a personal communication from R.W. Gould that allantoin was not a primary skin sensitizer in a Schwartz patch test on 200 people. Allantoin was nontoxic, nonirritating, and nonallergenic. Allantoin was not a primary skin irritant or primary sensitizer in a repeated-insult test of 12 people.
Akema Fine Chemicals 11 reported no irritation and no sensitization using allantoin on healthy volunteers (n ¼ 200; details not provided).
Tronnier 80 performed a skin irritation test on volunteers (n ¼ 50; 31 females, 19 males; 18-72 years old). Eleven of the subjects had allergies and 7 had sensitive skin. A plaster of allantoin (2-5 mg/cm 2 ) was applied to the backs of the volunteers. The test plaster was removed after 24 hours. The test area was observed at removal of the plaster and after 72 hours. There were no signs of irritation.
Consumer Product Testing Co 81 performed a repeated-insult patch test of a product containing allantoin (0.095%) on human subjects (n ¼ 105; age 16-78 years). The product (*0.2 mL) was applied to the upper back under an absorbent pad 3 times a week for 9 applications. The pad was left in place for 24 hours. After *2 weeks' rest, a challenge pad was applied to a naive site and read 24 and 72 hours after application. There were scattered, transient, barely perceptible to moderate responses with occasional dryness and/or edema noted throughout the test period. No evidence of induced allergic contact sensitization was observed. The authors concluded that the results did not indicate a clinically significant potential for dermal irritation or allergic contact sensitization.
The Personal Care Products Council 82 submitted summaries of tests of products containing allantoin. In a 21-day cumulative irritation study, baby talc containing allantoin (0.5%) was repeatedly applied, under occlusion, to volunteers with self-perceived sensitive skin (n ¼ 33). No skin irritation was detected with a normalized score of 0.00 out of 630. In a second test of the same product, with volunteers with self-perceived sensitive skin (n ¼ 35), no skin irritation was detected with a normalized score of 8.9 out of 630.
In a repeated-insult patch test of baby talc containing allantoin (0.5%), the product was applied to volunteers with normal skin (n ¼ 214). There were no reactions to 212 volunteers during induction (2 volunteers with a minimal or doubtful response). There were no reactions during the challenge phase.
This study was repeated with volunteers with normal skin (n ¼ 213). During the induction phase, there were no reactions for 211 volunteers (2 volunteers with minimal or doubtful responses). There were no reactions during the challenge phase.
This study was repeated with volunteers with normal skin (n ¼ 206). During the induction phase, there were no reactions in all volunteers. There were no reactions during the challenge phase. 82 Other Dermal Tests Mecca 83 stated that when allantoin is used in shampoos, not all of the allantoin is washed away, but rather some is left on the scalp and in the hair.
Henning 84 tested the effects of allantoin on stratum corneum renewal by applying a cream containing allantoin (0.5%) twice a day to untreated skin on forearms (number of subjects not stated). Another area was treated with a placebo and another was untreated. A suspension of dansyl chloride in petrolatum was applied to the forearm skin, and the level of fluorescence was assessed every second day under UV light. The time taken for dansyl chloride to disappear provided a measure of stratum corneum renewal time. Untreated skin had a renewal time of *23 days, placebo *21 days, and allantoin-treated skin *19 days. No adverse effects were reported.
In a second experiment, irritation on the volar skin of forearms (number of subjects not stated) was induced by sodium dodecyl sulfate-tape stripping and UV radiation. Redness was measured with a chromatometer before irritation and after 2 hours and 1, 3, and 5 days. The skin was untreated, treated with a placebo (*2 mg/cm 2 ), or treated with the cream containing allantoin (0.5%; *2 mg/cm 2 ). Before irritation, redness was measured at *8.4. Allantoin-treated skin had lower redness scores at all observation times (no statistics were reported). No adverse effects were reported.
In a third experiment, transepidermal water loss (TEWL) was measured before treatment with sodium dodecyl sulfate, after treatment, and then after treatment as in the above experiments (number of subjects not stated). TEWL was closer to normalized in the allantoin-containing cream-treated group on day 5 than in the other 2 groups. 84 Vinson and Proch 85 tested the use of an allantoin-based protectant as a moisture barrier in 12 subjects. The product containing allantoin (concentration not provided) was applied to 1-inch-square areas of the forearm and then covered with a bandage treated with a saline solution that simulated the density and ionic strength of urine and contained a dye solution. No reactions were reported from the allantoin barrier product at
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Skin Disease Treatment
Topical agents containing allantoin and other ingredients were tested for effectiveness in treatment of diaper rash in infants.
No adverse effects were reported in the studies. 86, 87 Studies of topical agents containing allantoin and refined coal tar extract in treating psoriasis or other skin conditions reported no adverse effects. [88] [89] [90] [91] [92] In another study, 22 patients were treated with an ointment containing allantoin, coal tar extract, and other ingredients. 93 One adverse side effect (acute dermatitis) was reported.
Almeyda and Wood 94 compared an allantoin (2%)-coal tar (5%) cream-based treatment to a fluorinated steroid preparation for the treatment of psoriasis on 33 patients (17 male, 16 female; age 16-74 years). The former was applied to the left arm and the latter to the right arm 2 or 3 times a day after an initial evaluation. The progress was evaluated after 2 and 4 weeks. Two patients dropped out because of deteriorating conditions. The allantoin-coal tar preparation performed better in 8 cases, worse in 13 cases, and equally well in 7 cases, and it failed equally in 7 cases. Six patients dropped out after the 2week evaluation, 1 because of worsening of the condition with the allantoin-coal tar preparation that included a secondary infection. No other adverse effects were reported.
Wound Treatment
Creams, gels, and ointments containing allantoin (alone or in combination with other ingredients) have been tested for wound healing and treatment of other skin conditions. 56, [94] [95] [96] [97] No adverse effects attributed to allantoin were reported.
Galacturonic acid and polygalacturonic acid. No relevant safety test data were found on galacturonic acid and polygalacturonic acid. Galacturonic acid, in the form of polygalacturonic acid, is a major component of the polysaccharides that form pectin. Pectin is a group of polysaccharides rich in galacturonic acid. Galacturonic acid is present in the following major structural features that form the backbone of polysaccharide domains that are thought to be found in all pectin species: homogalacturonan, rhamnogalacturonan-I, and rhamnogalacturonan-II. 98, 99 Homogalacturonan is a homopolymer of (1-4)-a-Dgalacturonic acid residues that may be methylesterfied and acetylated. Rhamnogalacturonan-I has a repeating backbone of (1-2)-a-L-rhamnose-(1-4)-a-D-galacturonic acid. Rhamnogalacturonan-II has a homogalacturonan backbone with oligosaccharide side chains, as in Figure 3 . 98, 99 The FDA has deemed pectin as GRAS when used as a direct human food additive. 47 
Summary
This safety assessment includes the cosmetic ingredient allantoin and its related complexes: allantoin ascorbate, allantoin biotin, allantoin galacturonic acid, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid. The safety of ascorbic acid, biotin, glycyrrhetinic acid, and panthenol has already been assessed by the CIR Expert Panel, and these agents were found to be safe. Galacturonic acid and polygalacturonic acid have not been reviewed by the CIR Expert Panel. Galacturonic acid is a sugar that is a component of pectin.
Polygalacturonic acid is the polysaccharide of the acid. Pectin was deemed GRAS as a direct human food additive by FDA.
Allantoin is a heterocyclic organic compound that may be prepared by several methods, including uric acid oxidation in the presence of permanganate. The other ingredients in this assessment are organic salts of this compound, except for allantoin panthenol, which is an alcohol/heterocyclic compound complex. Multiple analytical methods for allantoin are reported, including HPLC. Impurities include sulphated ash, sulphate, chloride, lead, arsenic, urea, and glycoluril.
All of the ingredients in this review act as skin-conditioning agents -miscellaneous.
Allantoin was reported to be used in 1376 cosmetic products at concentrations ranging from 0.0001% to 2%. Allantoin ascorbate was reported to be used at concentrations of 0.001% and 0.05%. Allantoin glycyrrhetinic acid was reported to be used in 6 cosmetic products, allantoin panthenol in 2 cosmetic products, and allantoin polygalacturonic acid in 2 cosmetic products. There were no reported uses for allantoin biotin or allantoin galacturonic acid. Allantoin, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid were reportedly used in hair sprays. Noncosmetic uses included wound treatment and skin protectant. Allantoin is found in plants and foods. Mammals process purines to allantoin with the exception of higher apes and humans because of their lack of urate oxidase. Only small amounts of allantoin are produced by oxidation of uric acid by cytochrome c and other oxidation pathways.
There was 98% recovery of allantoin in urine in dogs 5 hours after intravenous administration. When allantoin was administered orally, elimination was complete at 4 hours. Recovery averaged 66% when allantoin was administered in feed. No urinary allantoin was recovered from rabbits with allantoin in the diet. In sheep, most of the intravenously administered allantoin was excreted in the urine; degradation in the gut occurred post ruminally.
Acute oral toxicity of allantoin was greater than 5000 mg/kg in rats. Acute dermal toxicity of allantoin was equal to 5000 mg/kg in rabbits with intact and abraded skin.
Allantoin was nonirritating when instilled into the eyes of rabbits. Allantoin at 0.5% is not a dermal irritant to the intact or abraded skin of rabbits.
Allantoin was not mutagenic in an Ames test. When fed to rats at 28 g per female and 42 g per male over 2 years, allantoin did not increase the instances of neoplastic lesions and tumors compared with controls. Allantoin with nitrite increased the incidence of papillomas of the forestomach in males and reduced the incidence of pituitary tumors in females without nitrite. There was no difference in life spans between rats fed allantoin and controls.
In a fasting blood clinical test, serum allantoin levels were 10.8 + 1.7 mmol/L for women and 13.4 + 1.6 mmol/L for men. Individual urinary recovery of orally administered allantoin to human males was 18.6% in 24 hours and 33.8% in 72 hours. Intravenously administered allantoin recovery in the urine was 98% in 72 hours and 94.5% and 88.8% in 12 hours. Subcutaneously administered allantoin recovery in the urine was 81.2% in 6 hours and 73.2% in 24 hours.
Allantoin (1%) penetration of human skin after 3-and 6-hour exposures was 5.00% + 1.25% and 6.9% + 1.4% in a hydrophilic gel, 13.0% + 1.8% and 15.4% + 2.7% for an oil/water cream, and 12.5% + 2.1% and 20.0% + 2.3% for a water/oil ointment, respectively.
Allantoin was found to be clinically nonirritating and nonsensitizing in multiple tests at various concentrations in various vehicles up to 0.5%.
Allantoin-containing medications were tested for effectiveness and were successful in treating and preventing diaper rash in infants. No adverse effects were reported for the babies or the persons applying the medication. Medications containing allantoin (2%)-coal tar successfully treated patients with psoriasis with no adverse effects. Allantoin-containing treatments, up to 4%, successfully treated psoriasis patients; 1 of 22 patients using an allantoin-coal tar lotion developed acute dermatitis after 1 week. Application of a coal tar lotion with allantoin (2%) 1 to 4 times daily for 6 months resulted in no adverse effects. A treatment containing allantoin (0.35%) in 40 patients with seborrheic dermatitis reported 1 adverse event. There were no adverse effects in the treatment of skin conditions with allantoin up to 2%.
Discussion
The CIR Expert Panel noted that none of the sensitization and irritation safety test studies were conducted at the 2% level, which is reported to be used in cosmetics. However, the therapeutic use studies were conducted at 2% to 4% on damaged skin with no adverse effects. These clinical data were considered to support the safety of allantoin in cosmetics.
The panel noted that allantoin is a natural metabolic product for which no reproductive/developmental toxicity has been suggested.
The ingredients in the complexes were found to be safe in previous safety assessments. Pectin is a GRAS substance that is mostly made up of galacturonic and polygalacturonic acid. These allantoin complexes, as well as allantoin polygalacturonic acid and allantoin galacturonic acid, were not expected to be toxic.
The potential adverse effects of inhaled aerosols depend on the specific chemical species, the concentration and the duration of the exposure, and their site of deposition within the respiratory system. The reported mean diameter of particles in hair sprays is 38 mm, with other reported diameters of 60 to 80 mm. Because the aerodynamic diameters of respirable particles are less than 10 mm, most aerosol particles found in hair sprays are not respirable. In the absence of inhalation toxicity data, the panel determined that allantoin and its related complexes can be used safely in hair sprays, because the ingredient particle size is not respirable.
The CIR Expert Panel recognizes that there are data gaps regarding use and concentration of these ingredients. However, the overall information available on the types of products in which these ingredients are used and at what concentrations indicates a pattern of use, which was considered by the Expert Panel in assessing safety.
Conclusion
The CIR Expert Panel concluded that allantoin and its related complexes, allantoin ascorbate, allantoin biotin, allantoin galacturonic acid, allantoin glycyrrhetinic acid, allantoin panthenol, and allantoin polygalacturonic acid, are safe as cosmetic ingredients in the practices of use and concentrations as described in this safety assessment. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in the group. 
Authors' Note

Declaration of Conflicting Interests
No potential conflict of interest relevant to this article was reported. F. Alan Andersen, PhD, and Lillian C. Becker are employed by the Cosmetic Ingredient Review.
94S
International Journal of Toxicology 29( Supplement 2) 
